Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Alzheimer Disease

Jobs That Save Lives? People In Certain Professions May Be At Reduced Risk Of Alzheimer's Death

Professions requiring constant navigation, such as taxi and ambulance drivers, might be at an advantage as a recent study found these workers have a reduced risk of death from Alzheimer's disease.

Medical Daily

New study will use phone apps to explore link between sleep and Alzheimer's risk

Cambridge University and UCL will collaborate with a tech company to explore how sleep tracking data can help detect Alzheimer's disease

Tom’s Guide

These surprising professions have the lowest rate of Alzheimer’s disease deaths

Alzheimer’s disease is a form of dementia and it is one of the leading causes of death in the United States

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Does menopause hormone therapy increase or decrease your risk of dementia? Here’s the science

By 2050, around 135 million people worldwide will be living with dementia. The most common cause of dementia is Alzheimer’s disease. Women are more likely than men to develop Alzheimer’s disease, even after accounting for women living longer.

The Conversation

AI supercharged the sciences in 2024, revealing a major breakthrough in Alzheimer's diagnosis

A surge of AI-powered breakthroughs reminds us of the good that artificial intelligence can do, when placed in the right hands.

Laptop

How one health concern could predict Alzheimer’s disease decades before first symptoms occur

Alzheimer’s disease affects millions of Americans and is one of the top 10 causes of death in the U.S.

The Independent UK

Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial

IGC Pharma, Inc.(NYSE:IGC) reported additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1 for agitation in dementia associated with Alzheimer's disease. IGC-AD1 targets neuro-inflammation and CB1 receptor dysfunction,. The investigational drug contains THC as one of two active pharmaceutical agents.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Vulnerability to financial scams in aging adults could be an early indicator of Alzheimer’s disease, new research shows

A brain region affected very early in Alzheimer’s disease may explain why some aging people are at greater risk of financial exploitation. That is the key finding of our new study, published in the journal Cerebral Cortex.

The Conversation

Study finds how Alzheimer's disease may damage brain in two phases

Alzheimer's disease may cause brain damage in two stages, according to new research supported by the National Institutes of Health (NIH) that uses sophisticated brain mapping methods. Read further on Dynamite News:

Dynamite News

Blood test could ‘reliably rule out’ Alzheimer’s, trial finds

There are hopes it will offer reassurance to patients with cognitive decline and help them avoid unnecessary further testing, researchers said.

Evening Standard

Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

The Conversation

Fell for a Financial Scam? Might Be Time to Test for Alzheimer's

Falling for financial scams may be an early indicator of Alzheimer's among older adults.

Kiplinger

Ozempic Outperformed 7 Diabetes Medications in Reducing the Risk for Alzheimer’s Disease

Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 million patients with type 2 diabetes.

Inverse

Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns

Campaigners say decision is ‘frustrating setback’ for people living with disease

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

Evening Standard

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

The Independent UK

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

The Conversation

Why light pollution may be linked to greater risk of Alzheimer’s disease

Light pollution is a growing issue. Over the past 25 years, artificial lighting has surged by 49% worldwide. For perspective, the brightness of the night sky has risen by almost 10% per year over the last 12 years. Around 80% of the global population is now affected by light pollution.

Get all your
news in one place.

100’s of premium titles.
One news app.

GoodToKnow

Which parent is more likely to pass down Alzheimer’s disease? New research has the answer

Alzheimer's can be passed down from parents to children, but new research reveals whether a particular parent is more likely to be responsible.

Medical Daily

Excessive Exposure To Night Light Linked To Higher Risk Of Alzheimer's: Study

Excessive light pollution increases the risk of Alzheimer's in both older and younger adults. For those under 65, nighttime light exposure poses a greater risk of developing Alzheimer's disease compared to many other known factors.

The Independent UK

Picking your nose could contribute to risk of Alzheimer’s disease, study finds

A letter citing 10 studies, published by the American Journal of the Medical Sciences, says picking your nose could increase risk of dementia

The Conversation

Research shows diabetes drug could reduce dementia risk. Here’s how the two diseases may be linked

A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be at a significantly lower risk of dementia.

The Independent UK

What are the symptoms and treatments for Alzheimer’s – as new drug is rejected

Lecanemab has been deamed too expensive for use on the NHS.

The Independent UK

What you need to know about lecanemab – the Alzheimer’s drug rejected for NHS use

The drug has been developed by Eisai, a Japanese pharmaceutical company, and is sold under the brand name Leqembi

The Independent UK

First drug to slow Alzheimer’s progression will not be made available on the NHS

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Michigan

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.